| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.034 | 0.8 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.8 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.006 | 0.8 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.028 | 0.8 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.8 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |